Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-06-25
2003-06-17
Romeo, David S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S094610, C530S350000, C930S240000
Reexamination Certificate
active
06579850
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a novel aging-suppressing polypeptide in animals, DNA encoding the polypeptide, an antibody recognizing the polypeptide, a ligand for the polypeptide of the present invention, a compound inhibiting a specific binding between the polypeptide and ligand of the present invention, and a compound enhancing the expression of an aging-suppressing gene encoding the aging-suppressing polypeptide of the present invention.
2. Brief Description of the Background Art
The aging phenomenon refers to deterioration of individuals, in terms of change in their functions and appearances, which is generally promoted by the advance in aging. It is known that the frequency of the onset of various adult diseases increases with aging. Therefore, pharmaceutical agents capable of controlling aging in a certain form are expected to be developed as therapeutic agents or preventive agents of adult diseases and as protective agents or preventive agents against functional and apparent deterioration. However, no pharmaceutical agents having these scientifically verified effects have been reported.
Throughout the world, research directed to aging in individuals at the genetic. level has just started, and no molecular genetics information relating to aging in individuals has been presented so far. However, several types of genetic premature aging syndromes are known, including Werner's syndrome, Hutchinson-Gilford syndrome (progeria), Down's syndrome, Turner's syndrome, Louis Barr's syndrome, Rothmond Thomson syndrome and the like (Daizabuzo Fujimoto, eds.,
Mechanism and Control of Aging,
IPC, 1993).
The causative gene of Werner's syndrome has been identified as the gene encoding helicase [
Science,
272: 258 (1996)]. Various mutations have been observed in the genes from the patients with Werner's syndrome. It is believed that no normal helicase protein is produced in the patients due to the mutation of the gene and, therefore, its function is not expressed so that a syndrome resembling premature aging may develop.
Based on the above, a suggestion has been presented that a gene relating to aging is present and that aging is promoted through the mutation of the gene. Because other causative genes are also present for other types of genetic premature aging syndromes, it is believed that a plurality of genes may be involved in aging.
If an aging syndrome occurs as a result of loss in function of a gene involved in aging, therapeutic treatment would be useful, such treatment comprising supplementing the function of the gene, i.e. administering a protein product encoded by the gene or expressing the protein product in genetic treatment fashion. Also, if aging can be controlled, except for a genetic premature aging syndrome, various adult diseases occurring in close relation to aging would be treated or prevented.
The gene of the present invention is different from the causative gene of Werner's syndrome.
SUMMARY OF THE INVENTION
No measure is known for treating, preventing or diagnosing adult diseases of which the frequency of the occurrence increases based on aging; for protecting, preventing or diagnosing functional and apparent deterioration based on aging; or for treating and diagnosing a premature aging syndrome. The present invention is useful for such a measure.
The present invention relates to a polypeptide having an activity of suppressing aging in animals including humans; a therapeutic agent for a syndrome resembling premature aging, a therapeutic agent for adult diseases or an aging-suppressing agent, each comprising the polypeptide; DNA encoding the polypeptide; a therapeutic agent for a syndrome resembling premature aging, a therapeutic agent for adult diseases or an aging-suppressing agent, each comprising the DNA; a method for improving livestock using the DNA; a recombinant DNA prepared by inserting the DNA into a vector; a transformant harboring the recombinant; a method for producing the polypeptide of the present invention using the transformant; an antibody recognizing the polypeptide; a method for detecting the polypeptide of the present invention or a method for diagnosing aging, each using the antibody; a method for screening a ligand for the polypeptide of the present invention; the ligand; a method for screening a compound inhibiting a specific binding between the polypeptide and ligand of the present invention; and a compound prepared by the screening method.
BRIEF DESCRIPTION OF THE DRAWINGS
The symbols used in the drawings are described below.
bp: base pairs
kb: kilobase pairs
IFN-&ggr;: interferon-&ggr; gene
Amp, Ap or Ap
r
: ampicillin resistant gene derived from pBR322
rop
+
: rop gene
PletI: letI promoter
Ptrp: trp promoter
P
SE
: simian virus 40 (SV40) early gene promoter
P
MO
: long terminal repeat (LTR) promoter of Molony mouse leukemia virus
Hyg: hygromycin resistant gene
G418
r
: G418 resistant gene
dhfr: dihydrofolic acid reductase gene
P1: P1 promoter derived from pBR322
Ptk: promoter of herpes simplex virus (HSV) thymidine kinase (tk) gene
Sp.&bgr;G: rabbit &bgr;-globin gene splicing signal
A.&bgr;G: rabbit &bgr;-globin gene poly(A) addition signal
A.SE: simian virus 40 (SV40) early gene poly(A) addition signal
Atk: poly(A) addition signal of herpes simplex virus (HSV) thymidine kinase (tk) gene
REFERENCES:
patent: 5302706 (1994-04-01), Smith
patent: 5-506148 (1993-09-01), None
patent: 7-502651 (1995-03-01), None
patent: 91/15226 (1991-10-01), None
Martin et al. Ageing: New mice for old questions. Nature 390, 18-19 (Nov. 06, 1997).*
Bowie et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science, (Mar. 16, 1990) 247 (4948) 1306-10.*
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495.*
Roush W. Fast-forward aging in a mutant mouse? Science Nov. 7, 1997;278(5340):1013.*
Henikoff et al. Gene families: the taxonomy of protein paralogs and chimeras. Science. Oct. 24, 1997;278(5338):609-614.*
Wu et al. Neutralization of heparin activity by neutrophil lactoferrin. Blood, (Jan. 15, 1995) 85 (2) 421-8.*
Tomasetto et al. hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma. EMBO J Feb., 1990;9(2):407-14.*
Playford et al. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology Jan. 1995;108(1):108-16.*
Mian IS. Sequence, Structural, Functional, and Phylogenetic Analyses of Three Glycosidase Families. Blood Cells Mol Dis. Apr. 1998; 24(1):83-100.*
Database Accession No. H28389 XP-002213894, Hillier, et al., “y152e03.r1 Soares Breast 3NbHBst Homo sapiens . . . ” (1995).
Database Accession No. AAT27160 XP-002213952, Kakizuka, et al., “Human Machado-Joseph Disease Gene Probe” (1996).
Database Accession No. AAQ69624 XP-002213953, Andrews, et al., “Human bc1-2 proto-oncogene, target region”.
Database Accession No. R63458 XP-002214179, Hillier, et al., “yi08a10.r1 Soares placenta Nb2HP Homo Sapiens . . . ” (1995).
Database Accession No. P09848 XP-002213895, Mantei, et al., “Lactase-phlorizin hydrolase precursor” (1989).
Database Accession No. AB005141 XP-002213896, Kuro-O, et al., “Mus musculus klotho mRNA, complete cds.” (1997).
Database Accession No. AB005142 XP-002213897, Kuro-O, et al., “Homosapients klotho mRNA, complete cds.” (1997).
Nature, 390: 45-51 (1997).
Nature, vol. 390 (Nov. 6, 1997), pp. 45-51.
Science, vol. 272 (Apr. 12, 1996), pp. 258-262.
Science, vol. 269 (Sep. 1, 1995), pp. 1236-1241.
Nature, vol. 366 (Dec. 16, 1993), pp. 701-704.
Experimental Cell Research, vol. 199 (1992), pp. 355-362.
Iida Akihiro
Kuroo Makoto
Nabeshima Youichi
Sekine Susumu
Kyowa Hakko Kogyo Co. Ltd.
Romeo David S.
LandOfFree
Polypeptide, novel DNA and novel antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide, novel DNA and novel antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide, novel DNA and novel antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3154061